Claire F. Verschraegen

The Ohio State University — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

54h-index11.0kcitations510works1.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Research and Treatments(73), interferon and immune responses(63), Ovarian cancer diagnosis and treatment(51), Lung Cancer Research Studies(46), Cancer Immunotherapy and Biomarkers(41)

Publications509 total

Clinical Importance of Molecular Biomarkers in Pleural Mesothelioma
Cancers·2026Open Access
Rethinking combination strategies in metastatic castration-resistant prostate cancer (mCRPC)—lessons from KEYNOTE-641
Translational Andrology and Urology·2026Open Access
Integrated multiomic profiling of breast cancer in the Chinese population reveals patient stratification and therapeutic vulnerabilities
UNC Libraries·2025Open Access
Supplementary Figure S1 from Phase I Study of SYNB1891, an Engineered <i>E. coli</i> Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies
2025Open Access
Supplementary Figure S4 from Phase I Study of SYNB1891, an Engineered <i>E. coli</i> Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies
2025Open Access
Supplementary Figure 5 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
2025Open Access
Supplementary Figure S6 from Phase I Study of SYNB1891, an Engineered <i>E. coli</i> Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies
2025Open Access
Supplementary Tables 1-5 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
2025Open Access
Supplementary Figure S3 from Phase I Study of SYNB1891, an Engineered <i>E. coli</i> Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies
2025Open Access
Supplementary Table S2 from Phase I Study of SYNB1891, an Engineered <i>E. coli</i> Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies
2025Open Access
Supplementary Figure 2 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
2025Open Access
Supplementary Figure 1 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
2025Open Access
Supplementary Figure S7 from Phase I Study of SYNB1891, an Engineered <i>E. coli</i> Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies
2025Open Access
Supplementary Table S1 from Phase I Study of SYNB1891, an Engineered <i>E. coli</i> Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies
2025Open Access
Supplementary Figure S2 from Phase I Study of SYNB1891, an Engineered <i>E. coli</i> Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies
2025Open Access
Supplementary Figure S5 from Phase I Study of SYNB1891, an Engineered <i>E. coli</i> Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies
2025Open Access
Supplementary Figure S8 from Phase I Study of SYNB1891, an Engineered <i>E. coli</i> Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies
2025Open Access
Supplementary Figure 4 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
2025Open Access
Supplementary Figure 3 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
2025Open Access
Chemoprophylactic effect of PD-1/PD-L1 inhibitor treatment on non-melanoma skin cancer development
Journal of the American Academy of Dermatology·2025
page 1 of 26Next →

Frequent Co-authors

Ralph S. Freedman(13), Andrzej P. Kudelka(12), J. J. Kavanagh(8), John J. Kavanagh(7), Creighton L. Edwards(6), Hugo Arias‐Pulido(5), Lawrence B. Levy(4), Raffit Hassan(4), M Steger(4), Yi Xiao(3), Virginia Kaklamani(3), Zhi‐Ming Shao(3), Harriet O. Smith(3), Carolyn Y. Muller(3), Vincent Vinh‐Hung(3), M Hord(3), Nancy E. Joste(3), Saroj Vadhan‐Raj(3), Melanie Royce(3), Anish Thomas(3)